Todoxin, the immune stimulant from Serbia

Primary tabs

field_vote: 

From http://torexin.com/Cancer.html, http://torexin.com/dah_studija.html and http://torexin.com/hiv_aids.html


Issue 11/1998 of 08/06/1998
Introductory remark

In regard with so called "alternative" medicaments there has been a discussion going on for some time about a preparation called "TODoXIN". There is too little information on the effectiveness of this preparation, but the articles are circulating on the topic of "the medicine: 'TODoXIN'" expressing excitement or rejection. As far as we know, there are no underpinned contributions in which all the knowledge would be critically worked out and summarized. By the following detailed article we wish to fill this gap.

Introduction

"TODoXIN" is a herbal remedy which has been applied on over 7,000 patients in the cases of different (oncogen) viruses and against HIV-infection effects for 10 years. It was developed by Dr. Todor Jovanovic, a physician born in Vrani Do, Kosovo, in 1935. Dr. Jovanovic studied medicine in Belgrade and finished his specialization in Allergology. After the graduation he carried out research in the UN Research Centre for Nuclear Medicine and in military research centre in Vinca, near Belgrade. The main field of the research was search for histocompatible materials for implantats. Another field of intensive work was the research and monitoring of immunostimulating effects of plant extracts.

In 1987, Dr. Jovanovic applied for a patent on TODoXIN recipe. After that, he made an effort to get the support of experts and institutions in the country and abroad for his projects. There were, among others, the president of Serbian Academy of Science and Art, Dusan Kanazir, Luk Montagnier, the man who discovered HIV, as well as the leader of the special program of WHO for AIDS, Jonathan Man.

Because of the sparse data, no one showed interest for that project, except for the leader of a research group from Austria. With the Austrian partners in the research, Dr. Jovanovic signed a long-term contract on cooperation in 1988. The goal of the cooperation was to test the remedy on the international scale, galenic development and later, submission of the appropriate study results, obtaining the international approval and production.

After it has been proved toxicologically safe in 1988, the Austrian team, in collaboration with the Karolinska Institute for Immunology in Stockholm, in 1988-89, succeeded in showing the immunostimulating properties of TODoXIN in vitro, as well as the development of pharmacodynamic model of effect mechanisms induced on the immuoendocrinal level. That model could have been tested ex vitro and and confirmed in vivo. It was followed by intensive medical observation of its use, in collaboration with some clinical workers and physicians, in a wide spectrum of potential indications for immunostimulating properties of TODoXIN. On the basis of the data obtained by early 1991, the scientists of National Institutes of Health (NIH), in Washington, expressed their readiness to examine TODoXIN in vitro within the "Developmental Therapeutics Program". The studies of HIV culturing proved that cell bearable concentrations of active agents of TODoXIN can inhibit HIV up to 100%.

At the end of 1991 TODoXIN was given the license for production in Yugoslavia under the register number 4684 dd 31/10/88, as a "dietetic product based on honey and medicinal herbs ". The records on HIV- inhibiting capacity of TODoXIN, obtained at NIH, as well as the results of HIV-positive patients treated with TODoXIN since 1988, were not presented until the 10th International Conference on AIDS in Yokohama (1994), because NIH which was late in giving the permission for releasing the data.

On the basis of these data the Austrian research group succeeded in winning over the European virologists and AIDS researchers, prof. Richard Teddar and Dr. Clive Loveday from UCL Medical School of London, to the scientific collaboration. The data jointly won over the years that followed were appraised and designated as “very promising" by members of the British Medical Research Council – MRC and HIV Clinical Trial Centre – prof. A. Brackenridge, prof. D. Jeefries, prof. I. Weller and Dr J. Darbyshire.

On the 11. International AIDS Conference in Vancouver (1996), an official symposium on TODoXIN was held, where the most recent data were presented.

After that, the Department for Retro virology of Royal Free Medical School in London came up with offer to carry out further studies in England under official supervision of pharmaceutical authorities, MRC and one ethical committee. The results of these studies were supposed to support the official request for registration of TODoXIN in the European Union. The study started, after longer preparations, in September 1997, after it had been established that TODoXIN is to be produced in the future by Dr. Jovanovic together with an Austrian partner in the research, within one Austrian firm.

In the course of the study, Dr. Jovanovic decided to accept the offers of English researchers and their American partners to have TODoXIN produced in the USA in the future and to carry out further study over there. In order to present data which were up-to-date in 1998. to American partners, the London study, started in 1997, was interrupted in March 1998, and a new study was started, using the first laboratory samples of American TODoXIN. A separate American study is still about to start this year in California. Therefore, for the precaution sake, no new TODoXIN data were presented in the 12th International AIDS Conference in Geneva.


Composition

TODoXIN is made exclusively of plants and does not contain any synthetic components and preservatives.

Plants or parts of plants which are used for preparation are regularly tested for toxins which naturally occur, and for the presence of toxically substances used in agriculture (DDT, Lindan, Dieldrin, Endrin, Hexachlorbenzol, heavy metals, nitrites, nitrates, fungi, aerobic and anaerobic bacteria etc.)

In a joint poster session (abstract PA0340) presented by "TODoXIN Study Group" at 10th International AIDS Conference in Yokohama (1994) to the Department of Immunology of the Karolinska Institute (Sweden) and National Institutes of Health of the USA the composition of TODoXIN was presented in the following way:

"TODoXIN is a novel antiviral and immunostimulating preparation based upon an ion carrier molecule with specific binding affinities and a carrier specific substrate formulation. TODoXIN's formulation is unique in three aspects:

1. It comprises a very broad spectrum of physiologically active, cis-oriented and water soluble carbohydrates, carboxylic acids, vitamins, fat soluble vitamins, coenzymes and enzymes such as Amylases, Phosphates and Catalyses.

2. It contains both agonic and antagonic agents such as Ca and Fe, in physiologically relevant concentrations.

3. It contains a spectrum of minerals in permanent solution."

Micro-nutrients present in TODoXIN are exclusively of plant origin. They are obtained directly from fruits (mainly citrus fruits). Formulation also contains about 20 vol.-% honey.

Herbal active substance is kept in secret by Dr. Jovanovic. At present, there is a patent procedure running on the territory of the Former Yugoslavia. The exact composition, as well as pharmacokinetic data are not available for publication (not even in the editorial office). However, every therapeutic physician who would like to apply TODoXIN can have access to this data.


The up to date experience confirm the following indication:

myelo-proliferative syndrome

osteosarkoma

acute lymphoblast leukemia

acute myeloid leukemia

malignant lymphoma

adenocarcinom

testicular tumor, prostate, breast, rectum, cradle, lungs, skin and all gynecologist cancers.

 

There is hope even in case of very progressive diseases, like in lang metastasis, liver, bones. In many cases when patients were inoperable, because of diffusible infiltration of primary tumor into adjoining tissue and many metastasis even in case of bone decalcification, after TODOXIN therapy, the primary tumor is more clearly differentiated, looses in mass and becomes operable. Metastasis has disappeared, bones have been recalcificated and patients experienced complete remission. This phenomenon is 100 times more frequent than so called spontaneous remission in oncology practice.

However, it is most useful to start TODOXIN therapy as soon as the diagnosis has been established, for the effects are much better if it starts sooner. In progressive stadiums of cancer, a week can sometimes has the same significance as a whole year in different phases of cancer.

HIV/AIDS INFECTION

TODoXIN is in official use since 1963. Over 1300 HIV1 and 2 infected patients have been treated and the results are:

At patients whose virus serum was observed in short intervals, periodical appearance of HIV1 free virus (RNA virus serum) was noticed in the beginning of therapy during first 14 days of the high dose therapy cycles (taking every 2 hours).

 

There comes the increasing of 20 times above the average values and after that the gentle decreasing of virus serum which is on the detection limit (up to 4 log) in period between second and sixth week. Further on the value of virus serum constantly decreases (at detection limit, less than 20c/ml) after two to four cycles of the high dose therapy, that is 12-14 weeks.

After 6-18 months, the number of CD 4 cells increases for 50-150% of basic values and it happens with most patients. The time necessary for reaching and exceed the referent values is proportional to time extend of HIV infection before the therapy.

The significant changes during the therapy initiate the introduction of special forward therapy with corresponding dozes. This therapy deduces the clinical symptoms of viremia to minimum (to less than 2%).

Therapeutic Substance(s): 
Therapeutic intervention: